CXCL9-expressing tumor-associated macrophages can recruit a large number of CXCR3-expressing stem-like CD8+ T cells into TME, thus improving the efficacy of anti-PD(L)-1 treatment (29). This evidence concerns the gene CXCR3 and neoplasm.